FY2025 EPS Estimates for CervoMed Cut by HC Wainwright

CervoMed Inc. (NASDAQ:CRVO) – Equities research analysts at HC Wainwright reduced their FY2025 earnings per share estimates for CervoMed in a research report issued on Monday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($2.84) for the year, down from their prior estimate of ($2.60). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.64) EPS and FY2026 earnings at ($2.89) EPS.

CervoMed (NASDAQ:CRVO) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%. The business had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.43 million.

A number of other research analysts have also recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and issued a $31.00 target price on shares of CervoMed in a research note on Tuesday. Zacks Research cut shares of CervoMed from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and set a $15.00 price objective on shares of CervoMed in a report on Monday, August 11th. Finally, Roth Capital set a $20.00 target price on CervoMed and gave the stock a “buy” rating in a research report on Friday, October 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, CervoMed presently has a consensus rating of “Moderate Buy” and an average price target of $21.86.

CervoMed Stock Performance

CRVO opened at $7.41 on Wednesday. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $16.94. The firm has a 50-day moving average of $7.99 and a 200 day moving average of $8.18. The firm has a market cap of $68.56 million, a P/E ratio of -2.84 and a beta of -0.89.

Hedge Funds Weigh In On CervoMed

A number of hedge funds and other institutional investors have recently modified their holdings of the company. AWM Investment Company Inc. bought a new position in shares of CervoMed in the first quarter worth approximately $7,898,000. Jane Street Group LLC purchased a new stake in shares of CervoMed during the 2nd quarter valued at about $414,000. Nuveen LLC purchased a new stake in shares of CervoMed during the 1st quarter valued at about $312,000. Citizens Financial Group Inc. RI bought a new stake in shares of CervoMed in the first quarter worth approximately $244,000. Finally, Avantax Advisory Services Inc. purchased a new position in shares of CervoMed during the first quarter valued at approximately $238,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.